Bleomycin for older patients: less is more.

A. Moskowitz
DOI: https://doi.org/10.1182/blood-2016-03-699090
IF: 20.3
2016-05-05
Blood
Abstract:In this issue of Blood, Boll et al report on the toxicity of 2 vs 4 cycles of bleomycin-containing chemotherapy in older, early stage, favorable patients with Hodgkin lymphoma (HL) and show that 2 cycles, but no more, of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is well tolerated in this patient population.1
What problem does this paper attempt to address?